HT was observed 2.28 times more frequently in individuals with 25(OH)D3 levels
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: Vitamin D has been suggested to be active as an immunomodulator in autoimmune diseases such as Hashimoto's thyroiditis (HT).
📊
Key Findings & Data:The goal of the present study was to investigate the vitamin D status in HT patients.Methods: This prevalence case-control study was conducted on 90 patients with HT (of ages 12.32±2.87 years) and 79 age-matched healthy controls (11.85±2.28 years).
💡
Conclusion & Impact:HT was observed 2.28 times more frequently in individuals with 25(OH)D3 levels
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: Vitamin D has been suggested to be active as an immunomodulator in autoimmune diseases such as Hashimoto's thyroiditis (HT). The goal of the present study was to investigate the vitamin D status in HT patients.Methods: This prevalence case-control study was conducted on 90 patients with HT (of ages 12.32±2.87 years) and 79 age-matched healthy controls (11.85±2.28 years). Serum 25-hydroxyvitamin D3 [25(OH)D3] levels were measured in all 169 subjects.Results: The prevalence of vitamin D deficiency in HT patients (64 of 90; 71.1%) was significantly higher than that in the control group (41 of 79; 51.9%) (p=0.025). Mean serum 25(OH)D3 level in the HT group was significantly lower compared to the control group (16.67±11.65 vs. 20.99±9.86 ng/mL, p=0.001). HT was observed 2.28 times more frequently in individuals with 25(OH)D3 levels
🔖
Cite This Article
ERCAN, O., ERGİNÖZ, E., EVLİYAOĞLU, O., KUCUR, M., ÖZCABI, B., ACAR, M., BUCAK, F. (2022). Vitamin D Deficiency and Hashimoto's Thyroiditis in Children and Adolescents: a Critical Vitamin D Level for This Association?. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 7 - Sayı: 2, 128–133. https://ajindex.com/articles/562230
Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society.Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. Pediatrics 2008;122:398-417. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-2072. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266- 281. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(Suppl 6):1689-1696.
Deluca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J 2001;15:2579-2585.
Mathieu C, Adorini L. The coming of age of 1.25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002;8:174-179.
Schauber J, Dorschner RA, Coda AB, Büchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zügel U,Bikle DD, Modlin RL, Gallo RL. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007;117:803- 811. Epub 2007 Feb 8 Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH. Cutting edge: 1.25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909-2912.
Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1.25-dihydroxyvitamin D3. FASEB J 2005;19:1067- 1077. Koizumi T, Nakao Y, Matsui T, Nakagawa T, Matsuda S, Komoriya K, Kanai Y, Fujita T. Effects of corticosteroid and 1,24R-dihydroxyvitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP-lpr/ lpr mice. Int Arch Allergy Appl Immunol 1985;77:396-404.
Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, Martino G, Panina-Bordignon P, Adorini L. Inhibition of TH1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1.25-dihydroxyvitamin D(3). Eur J Immunol 2000;30:498- 508. Lemire JM, Archer DC. 1.25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107.
Cantorna MT, Hayes CE, DeLuca HF. 1.25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci